{"page_content": "35      KODIAK 2021 ESG REPORT BACK TO CONTENTS >>SASB SUSTAINABILITY ACCOUNTING STANDARDS 2018\nTopic SASB Code Accounting or Activity Metric Response, Cross-reference, or Omission Source(s)\nDrug SafetyHC-BP-250a.1List of products listed in the Food and Drug \nAdministration\u2019s (FDA) MedWatch Safety \nAlerts for Human Medical Products databaseNo products listed in the Food and Drug \nAdministration's (FDA) MedWatch Safety \nAlerts for Human Medical Products database \nbecause Kodiak is not yet in commercial \nproductionMedWatch Database\nHC-BP-250a.2Number of fatalities associated with products \nas reported in the FDA Adverse Event \nReporting System0 \n \nAs of December 2021, Kodiak is not yet in \ncommercial productionN/A\nHC-BP-250a.3 Number of recalls issued, total units recalled 0 \n \nAs of December 2021, Kodiak is not yet in \ncommercial productionN/A\nHC-BP-250a.4Total amount of product accepted for  \ntake-back, reuse, or disposalNot applicable as of December 2021 because \nKodiak is not yet in commercial production N/A\nHC-BP-250a.5Number of FDA enforcement actions taken \nin response to violations of current Good \nManufacturing Practices (cGMP), by type0 \n \nAs of December 2021, no known FDA \nenforcement actions have been taken in \nresponse to violations of current Good \nManufacturing Practices (cGMP). We outline  \ncompliance planning  with cGMP for future \ncandidates in 2021 10-K2021 10-K, p. 23\nCounterfeit \nDrugsHC-BP-260a.1Description of methods and technologies \nused to maintain traceability of products \nthroughout the supply chain and prevent \ncounterfeitingNot applicable as of December 2021 because \nKodiak is not yet in commercial production N/A\nHC-BP-260a.2Discussion of process for alerting customers \nand business partners of potential or known \nrisks associated with counterfeit productsNot applicable as of December 2021 because \nKodiak is not yet in commercial production N/A\nHC-BP-260a.3Number of actions that led to raids, seizure, \narrests, and/or filing of criminal charges \nrelated to counterfeit products0 \n \nNone to disclose as of December 2021 \nbecause Kodiak is currently in clinical trials \nand not yet in commercial productionN/AKODIAK 2021 SASB INDEX", "metadata": {"source": "NASDAQ_KOD_2021.pdf", "page": 34, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}